Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia.
Cerny-Reiterer S, Rabenhorst A, Stefanzl G, Herndlhofer S, Hoermann G, Müllauer L, Baumgartner S, Beham-Schmid C, Sperr WR, Mannhalter C, Sill H, Linkesch W, Arock M, Hartmann K, Valent P. Cerny-Reiterer S, et al. Among authors: herndlhofer s. Oncotarget. 2015 Feb 20;6(5):3071-84. doi: 10.18632/oncotarget.3074. Oncotarget. 2015. PMID: 25605011 Free PMC article.
Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy.
Aichberger KJ, Herndlhofer S, Agis H, Sperr WR, Esterbauer H, Rabitsch W, Knöbl P, Haas OA, Thalhammer R, Schwarzinger I, Sillaber C, Jäger U, Valent P. Aichberger KJ, et al. Among authors: herndlhofer s. Eur J Clin Invest. 2007 Oct;37(10):808-13. doi: 10.1111/j.1365-2362.2007.01859.x. Epub 2007 Aug 28. Eur J Clin Invest. 2007. PMID: 17727673
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics.
Wacheck V, Lahn M, Dickinson G, Füreder W, Meyer R, Herndlhofer S, Füreder T, Dorfner G, Pillay S, André V, Burkholder TP, Akunda JK, Flye-Blakemore L, Van Bockstaele D, Schlenk RF, Sperr WR, Valent P. Wacheck V, et al. Among authors: herndlhofer s. Cancer Manag Res. 2011;3:157-75. doi: 10.2147/CMR.S19341. Epub 2011 May 10. Cancer Manag Res. 2011. PMID: 21625399 Free PMC article.
Severe peripheral arterial disease during nilotinib therapy.
Le Coutre P, Rea D, Abruzzese E, Dombret H, Trawinska MM, Herndlhofer S, Dörken B, Valent P. Le Coutre P, et al. Among authors: herndlhofer s. J Natl Cancer Inst. 2011 Sep 7;103(17):1347-8. doi: 10.1093/jnci/djr292. Epub 2011 Aug 2. J Natl Cancer Inst. 2011. PMID: 21813414 No abstract available.
34 results